A detailed history of Verition Fund Management LLC transactions in Savara Inc stock. As of the latest transaction made, Verition Fund Management LLC holds 114,495 shares of SVRA stock, worth $358,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares
114,495
Previous 62,411 83.45%
Holding current value
$358,369
Previous $251,000 93.23%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.96 - $5.07 $206,252 - $264,065
52,084 Added 83.45%
114,495 $485,000
Q2 2024

Aug 14, 2024

BUY
$3.66 - $5.34 $165,508 - $241,480
45,221 Added 263.07%
62,411 $251,000
Q1 2024

May 14, 2024

BUY
$4.19 - $5.59 $72,026 - $96,092
17,190 New
17,190 $85,000
Q2 2018

Aug 15, 2018

SELL
$8.55 - $13.76 $87,457 - $140,751
-10,229 Closed
0 $0
Q1 2018

May 16, 2018

BUY
$8.99 - $14.95 $91,958 - $152,923
10,229 New
10,229 $94,000

Others Institutions Holding SVRA

About Savara Inc


  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $357M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.